Tigilanol tiglate  (Synonyms: EBC-46)

Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is a natural product with antitumor activity used for local administration against a variety of skin malignancies. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein response (UPRmt/ER) and subsequent induction of ATP depletion, organelles expansion, caspase activation, gasdermin E cleavage, and terminal necrosis. Tigilanol tiglate, as a small anti-tumor molecule with immunomodulatory effects, can be used in the study of head and neck squamous cell carcinoma and soft tissue sarcoma^[1].

562.65

C₃₀H₄₂O₁₀

943001-56-7

Solid

White to off-white

CC[C@H](C)C(O[C@@]12[C@@]([C@]3([H])[C@@]4([H])[C@](O4)([C@H]([C@]5([C@](C=C(C5=O)C)([H])[C@]3([C@@H]([C@H]2OC(/C(C)=C/C)=O)C)O)O)O)CO)([H])C1(C)C)=O

Room temperature in continental US; may vary elsewhere.

-20°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

• [1]. Cullen J K, et al. Tigilanol tiglate is an oncolytic small molecule that induces immunogenic cell death and enhances the response of both target and non-injected tumors to immune checkpoint blockade[J]. Journal for ImmunoTherapy of Cancer, 2024, 12(4).  [Content Brief]